BioScrip, Inc. (NASDAQ:BIOS) – Equities researchers at SunTrust Banks issued their Q4 2017 EPS estimates for BioScrip in a research note issued on Thursday. SunTrust Banks analyst D. Macdonald forecasts that the company will earn ($0.04) per share for the quarter. SunTrust Banks currently has a “Buy” rating and a $3.00 target price on the stock. SunTrust Banks also issued estimates for BioScrip’s Q1 2018 earnings at ($0.06) EPS, Q2 2018 earnings at ($0.05) EPS, Q3 2018 earnings at ($0.03) EPS, Q4 2018 earnings at ($0.01) EPS, FY2018 earnings at ($0.16) EPS, Q1 2019 earnings at ($0.04) EPS, Q2 2019 earnings at ($0.03) EPS, Q3 2019 earnings at ($0.02) EPS and FY2019 earnings at ($0.09) EPS.

BioScrip (NASDAQ:BIOS) last announced its earnings results on Thursday, November 2nd. The company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02). The company had revenue of $198.70 million during the quarter, compared to analyst estimates of $202.91 million. During the same period in the prior year, the company earned ($0.12) earnings per share. The firm’s quarterly revenue was down 11.5% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.watchlistnews.com/bioscrip-inc-expected-to-post-q4-2017-earnings-of-0-04-per-share-bios/1682489.html.

A number of other analysts have also issued reports on the company. ValuEngine lowered BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. BidaskClub downgraded BioScrip from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. Zacks Investment Research downgraded BioScrip from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $4.00 price objective (up from $3.00) on shares of BioScrip in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. BioScrip has a consensus rating of “Hold” and a consensus target price of $3.60.

Shares of BioScrip (BIOS) opened at $2.07 on Monday. BioScrip has a one year low of $0.98 and a one year high of $3.39. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11.

In related news, Director Coliseum Capital Management, L sold 886,478 shares of the stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $3.08, for a total transaction of $2,730,352.24. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Michael G. Bronfein sold 27,000 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $2.69, for a total value of $72,630.00. Following the sale, the director now directly owns 129,669 shares in the company, valued at approximately $348,809.61. The disclosure for this sale can be found here. Insiders have sold 3,760,419 shares of company stock worth $11,144,519 in the last quarter. 0.80% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of the business. Gilder Gagnon Howe & Co. LLC boosted its holdings in shares of BioScrip by 248.4% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 15,211,136 shares of the company’s stock valued at $41,298,000 after purchasing an additional 10,845,410 shares in the last quarter. FMR LLC lifted its stake in shares of BioScrip by 10.8% in the 2nd quarter. FMR LLC now owns 5,323,231 shares of the company’s stock valued at $14,453,000 after acquiring an additional 520,231 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of BioScrip by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,495,029 shares of the company’s stock valued at $12,204,000 after acquiring an additional 146,980 shares during the last quarter. Alta Fundamental Advisers LLC lifted its stake in shares of BioScrip by 36.9% in the 2nd quarter. Alta Fundamental Advisers LLC now owns 3,035,164 shares of the company’s stock valued at $8,240,000 after acquiring an additional 818,000 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of BioScrip by 10.0% in the 2nd quarter. State Street Corp now owns 1,815,439 shares of the company’s stock valued at $4,927,000 after acquiring an additional 165,091 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.